Norgine strengthens rare disease portfolio with acquisition of Theravia
Acquisition of Theravia from Merieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a...